17:00 EDT Design Therapeutics (DSGN) files $300M mixeds securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- Cautious Optimism for Design Therapeutics: Hold Rating Amid Promising Phase 1 Results and Extended Development Timeline
- Design Therapeutics announces data from Phase 1 SAD/MAD trial of DT-168
- RBC sees Makary interview as potentially positive for biotech stocks
- Design Therapeutics appoints Chris Storgard as CMO